Welcome to the e-CCO Library!

DOP05: Single-cell RNAseq temporal analysis of ulcerative colitis patients undergoing tofacitinib treatment reveals a shift in myeloid cells towards pro-inflammatory phenotypes in refractory patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Melon, E.(1)*;Veny, M.(1);Corraliza, A.M.(1);Garrido-Trigo, A.(1);Esteller, M.(1);Rodrigo, M.(2);Verstockt, B.(3);Vermeire, S.(4);Masamunt, M.C.(1);Giner, Á.(1);Ordás, I.(1);Fernández-Clotet, A.(1);Ricart, E.(1);Panés, J.(1);Salas, A.(1);
Created: Friday, 14 July 2023, 10:43 AM
DOP05: Target engagement and pharmacodynamic biomarker analysis following treatment with the oral gut-targeted HIF-1α stabilizer GB004 in a Phase 1b trial in Active Ulcerative Colitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Sandborn, W.(1);Ding, Z.(2);Osterhout, R.(2);Feagan, B.(3);Danese, S.(4);Jucov, A.(5,6);Bhandari, B.R.(7);Raghupathi, K.(8);Olson, A.(9);Van Biene, C.(8);Ford, J.(10);Aranda, R.(9);Levesque, B.G.(9);Bruey, J.M.(2)
Created: Wednesday, 2 June 2021, 4:12 PM
DOP06 Non-invasive identification of adherent-invasive E. coli in patients with Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Buisson1, E. Vazeille1, X. Hébuterne2, M. Fumery3, B. Pariente4, S. Nancey5, P. Seksik6, L. Peyrin-Biroulet7, M. Allez8, N. Ballet9, E. Billard10, S. Rodriguez10, B. Pereira11, N. Barnich10, CEALIVE Study Group

Created: Thursday, 30 January 2020, 10:12 AM
DOP060: Anti-TNF cord levels are significantly higher after IFX exposure during pregnancy compared with ADA exposure
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Kanis*1, A. de Lima1, C. van der Ent2, C. van der Woude1

Created: Friday, 22 February 2019, 9:49 AM
DOP060: Human amnion epithelial cells and their conditioned media reduces intestinal inflammation and fibrosis in a murine model of chronic colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

N. Kuk1,2*, J. Correia1,2, M. Alhomrani1,2,3, R. Lim3, W. Sievert1,2, A. Hodge1,2, G. Moore1,2

Created: Thursday, 21 February 2019, 9:14 AM
DOP060: Real-world treatment pathway visualizations show low use of biologic therapies in Crohn's disease and ulcerative colitis in the United States
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Siegel C.*1, Yang F.2, Eslava S.2, Cai J.2

Created: Wednesday, 20 February 2019, 10:36 AM
DOP061: Human amnion epithelial cells reduce intestinal inflammation in a 2,4,6-trinitrobenzene sulfonic acid induced model of acute colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

N. Kuk1,2*, J. Correia1,2, M. Alhomrani1,2,3, R. Lim3, W. Sievert1,2, A. Hodge1,2, G. Moore1,2

Created: Thursday, 21 February 2019, 9:14 AM
DOP061: Intrauterine exposure to thiopurine: assessing health outcome of children born to patients with an inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

S. Kanis*, A. de Lima, C. van der Woude

Created: Friday, 22 February 2019, 9:49 AM
DOP061: Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kim Y.H.*1, Ye B.D.2, Pesegova M.3, Alexeeva O.4, Osipenko M.5, Lahat A.6, Dorofeyev A.7, Salamon A.8, Fishman S.9, Levchenko O.10, Cheon J.H.11, Scribano M.L.12, Mateescu R.-B.13, Lee K.M.14, Eun C.S.15, Lee S.J.16, Lee S.Y.16

Created: Wednesday, 20 February 2019, 10:36 AM
DOP062: Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: explorative IBD subgroup-analyses in Crohn's disease and ulcerative colitis from the NOR-SWITCH trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Jørgensen K.K.*1, Olsen I.C.2, Goll G.L.2, Lorentzen M.3, Bolstad N.4, Berset I.P.5, Haavardsholm E.A.2,6, Lundin K.E.6,7,8, Mørk C.9, Kvien T.K.2,6, Jahnsen J.1,6 and the Nor-Switch Study Group

Created: Wednesday, 20 February 2019, 10:36 AM
DOP062: Malignancy and mortality in paediatric-onset inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

L. de Ridder1, M. Joosse*2, D. Turner3, D. Wilson4, S. Koletzko5, J. Martin-de-Carpi6, U. Fagerberg7, C. Spray8, M. Sladek9, R. Shaoul10, E. Roma-Giannikou11, J. Bronsky12, D. Serban13, S. Cucchiara14, G. Veres15, F. Ruemmele16, I. Hojsak17, K. Kolho18, I. Davies19, M. Aloi20, P. Lionetti21, G. Veereman-Wauters22, C. Braegger23, E. Trindade24, A. V. Wewer25, A. Hauer26, A. Levine27

Created: Friday, 22 February 2019, 9:49 AM
DOP062: The anti-MAdCAM antibody SHP647 in Crohn’s disease: Endoscopic effects of induction therapy
Year: 2018
Source: ECCO '18 Vienna
Authors:

G.R. D´Haens1*, K. Gorelick2, Y. Wang3, F. Cataldi3, W.J. Sandborn4

Created: Thursday, 21 February 2019, 9:14 AM
DOP063: Inhibition of tyrosine kinase 2 signalling ameliorates T cell transfer colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

L.C. De Vries1,2, M.E. Wildenberg1,2*, R.A. Willemze1,2, H.P. van Hamersveld1, O. Welting1, C. Verseijden1, B. Strobl3, M. Mueller3, G.R. D'Haens2, W.J. De Jonge1

Created: Thursday, 21 February 2019, 9:14 AM
DOP063: Measurement of endoscopic severity in a Crohns disease multicentre paediatric inception cohort: poor correlation of SES-CD with Paediatric Crohns Disease Activity Index (PCDAI)
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

N. Carman*1, P. Church1, H. Huynh2, D. Mack3, K. Jacobson4, A. Otley5, J. De Bruyn6, W. El-Matery7, C. Deslandres8, M. Carroll2, E. Wine2, E. Benchimol3, J. Van Limbergen5, A. Griffiths1, T. Walters1

Created: Friday, 22 February 2019, 9:49 AM
DOP063: Serial tuberculin skin test improves the detection of latent tuberculosis infection in inflammatory bowel disease patients
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Taxonera C.*1, Ponferrada A.2, Bermejo F.3, Gisbert J.P.4, Riestra S.5, Saro C.6, Cabriada J.L.7, Barreiro-de Acosta M.8, Barrio J.9, Flores E.10, Ferrer I.11, Hernandez A.12, Van Domselaar M.13, Olivares D.1, Alba C.1, Fernández-Salazar L.14, Merino O.15, Botella B.16, Ceballos D.17, Moral I.18, Peñate M.19, Algaba A.3 on behalf of the SEGURTB Study Group from GETECCU

Created: Wednesday, 20 February 2019, 10:36 AM
DOP064: Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

B. r*1, M. Yavzori1, O. Picard1, E. Fudim1, U. Kopylov1, E. Del Tedesco2, S. Paul2, Y. Chowers3, R. Eliakim1, S. Ben-Horin1, X. Roblin2

Created: Friday, 22 February 2019, 9:49 AM
DOP064: ECCO expert consensus and topical review on treatment exit strategies in inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

G. Doherty1*, K. Katsanos2, J. Burisch3, M. Allez4, K. Papamichael5, A. Stallmach6, R. Mao7, I. Prytz Berset8, J. Gisbert9, S. Sebastian10, J. Kierkuś11, L. Lopetuso12, E. Szymanska11, E. Louis13

Created: Thursday, 21 February 2019, 9:14 AM
DOP064: High rate of advanced neoplasia after detection of low-grade dysplasia in inflammatory bowel disease patients with primary sclerosing cholangitis
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ten Hove J.R.*1, Torres J.2, Castaneda D.2, Palmela C.2, Mooiweer E.1, Shah S.C.2, Colombel J.-F.2, Ullman T.2, Itzkowitz S.H.2, Oldenburg B.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP065: Less anti-infliximab antibody formation in paediatric Crohns patients on concomitant immunomodulators
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

H. Kansen1, P. van Rheenen2, R. Houwen1, W. Tjon A Ten3, G. Damen4, A. Kindermann5, J. Escher6, V. Wolters*1

Created: Friday, 22 February 2019, 9:49 AM
DOP065: Long-term cost-effectiveness of tight control for Crohn’s disease with adalimumab-based treatment: economic evaluation beyond 48 weeks of CALM trial
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Panaccione1*, J.-F. Colombel2, P. Bossuyt3, F. Baert4, T. Vanasek5, A. Danalioglu6, G. Novacek7, A. Armuzzi8, W. Reinisch7, S. Johnson9, M. Buessing9, E. Neimark10, J. Petersson10, A.M. Robinson10, R.B. Thakkar10, W.-J. Lee10, M. Skup10, G. D’Haens11

Created: Thursday, 21 February 2019, 9:14 AM